The following was reported to gore: on an unknown date, a gore® acuseal vascular graft (acuseal) was implanted as an arteriovenous graft.On (b)(6) 2020, a gore® viabahn® endoprosthesis with heparin bioactive surface (viabahn) was additionally implanted to treat occlusion at the venous anastomosis of the acuseal.On june 11, 2020, it was reported that the viabahn was occluded.On the same day, thrombectomy using a balloon catheter was performed to treat the occlusion, and blood flow was recovered.After that, platelet count was decreased, and it was revealed that heparin-induced thrombocytopenia (hit) antibody was positive.Therefore, heparin was discontinued and argatroban was administered.Platelet count was recovering.
|
Additional manufacturing narrative: c1.Name (#1) - cbas® heparin surface; manufacturer/compounder: w.L.Gore & associates, inc.Lot #17842998.Cbas® heparin surface incorporates cbas-heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.
|